Psychosomatic Disorders Terminated Phase 3 Trials for Midazolam (DB00683)

Also known as: Psychosomatic disorder

IndicationStatusPhase
DBCOND0063832 (Psychosomatic Disorders)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02374567Pharmacovigilance in Gerontopsychiatric PatientsTreatment